These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24050512)

  • 41. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
    Hu TH; Chuah SK; Hsu PI; Wu DC; Tai WC; Chiu YC; Wu KL; Kuo CM; Hu ML
    Am J Med Sci; 2011 Sep; 342(3):177-81. PubMed ID: 21804375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.
    Peitz U; Sulliga M; Wolle K; Leodolter A; Von Arnim U; Kahl S; Stolte M; Börsch G; Labenz J; Malfertheiner P
    Aliment Pharmacol Ther; 2002 Feb; 16(2):315-24. PubMed ID: 11860415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
    Liou JM; Chen CC; Chang CM; Fang YJ; Bair MJ; Chen PY; Chang CY; Hsu YC; Chen MJ; Chen CC; Lee JY; Yang TH; Luo JC; Chen CY; Hsu WF; Chen YN; Wu JY; Lin JT; Lu TP; Chuang EY; El-Omar EM; Wu MS;
    Lancet Infect Dis; 2019 Oct; 19(10):1109-1120. PubMed ID: 31559966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
    Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
    Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Suo B; Tian X; Zhang H; Lu H; Li C; Zhang Y; Ren X; Yao X; Zhou L; Song Z
    Chin Med J (Engl); 2023 Apr; 136(8):933-940. PubMed ID: 37010246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
    Lee BH; Kim N; Hwang TJ; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Helicobacter; 2010 Feb; 15(1):38-45. PubMed ID: 20302588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Three treatment schemes with colloidal bismuth subcitrate (Q-ULCER) in peptic ulcer with Helicobacter pylori.
    Suárez MS; González Cansino J; Velasco Ilizalde C; Sabatier CA; Castillo Hernández J
    Arch Med Res; 1999; 30(1):55-9. PubMed ID: 10071426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quadruple therapy versus standard triple therapy for eradication of Helicobacter pylori in Kuwait.
    Alboraie M; Saad M; Al-Ali J; Malik M; Asem N; Schmidt I; Alfadhli AA
    Arab J Gastroenterol; 2015; 16(3-4):131-5. PubMed ID: 26611765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.
    Marušić M; Dominković L; Majstorović Barać K; Gulić S; Bago J; Pezerović D
    Minerva Gastroenterol Dietol; 2017 Jun; 63(2):80-84. PubMed ID: 27973462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.
    Guevara B; Cogdill AG
    Dig Dis Sci; 2020 Jul; 65(7):1917-1931. PubMed ID: 32170476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
    Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
    Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.
    Isakov V; Domareva I; Koudryavtseva L; Maev I; Ganskaya Z
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1277-82. PubMed ID: 12144577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized comparison of two rescue therapies for Helicobacter pylori infection.
    Wu DC; Hsu PI; Chen A; Lai KH; Tsay FW; Wu CJ; Lo GH; Wu JY; Wu IC; Wang WM; Tseng HH
    Eur J Clin Invest; 2006 Nov; 36(11):803-9. PubMed ID: 17032348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
    Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
    Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.
    Sacco F; Spezzaferro M; Amitrano M; Grossi L; Manzoli L; Marzio L
    Dig Liver Dis; 2010 Feb; 42(2):110-4. PubMed ID: 19846355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial.
    Mirbagheri SA; Hasibi M; Abouzari M; Rashidi A
    World J Gastroenterol; 2006 Aug; 12(30):4888-91. PubMed ID: 16937475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.